Replies to post #183 on Heron Therapeutics Inc. (HRTX)

[mo282]

please read this again:

A.P. Pharma's APF530 Phase 3 clinical trial demonstrated that it can deliver therapeutic levels of granisetron to prevent acute onset CINV for both moderately and highly emetogenic chemotherapy, and to prevent delayed onset CINV in moderately emetogenic chemotherapy.------So basically it does do what aloxi does currently---- The sector efficacy data involving delayed onset CINV in highly emetogenic chemotherapy showed results for the higher dose of APF530 that were numerically better than palonosetron and statistically non-inferior, but did not achieve the statistically significant level of superiority necessary to support a claim in this sector. If A.P. Pharma obtains product approval for all uses except the delayed onset highly emetogenic one, the Company should have a product comparable to palonosetron, ----EXCEPT! it lasts 2 days longer than aloxi, where aloxi lasts 3 and this , 5, this is a big deal as you have insurance costs each time drugs are administered and ofcourse patient preference , where they need to take it less often.